In prostate cancer, new loops with specific histone modifications may serve as new diagnostic markers; the TMPRSS2-ERG fusion has been used as a marker in diagnosis and risk assessment for many years, even before chromatin loops were identified as the culprit [102]. This evidence concerns the gene TMPRSS2 and prostate carcinoma.